drugset / Trial / NCT00626639

A Study of Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy and Concurrent Chemotherapy

NCT00626639

Phase 1/2 Completed 5 enrolled Swedish Orphan Biovitrum Amgen · collab
RandomizedParallel-groupDouble-blindSupportive care

Summary

Oral Mucositis associated with adjuvant radiation and concurrent chemotherapy in postoperative Head and Neck setting

Timeline

Start
2005-07
Primary completion
2007-05
Completion
2015-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Palifermin Protein / enzyme biologic 120 ug/kg Intravenous
Background Cisplatin Other / unclassified 100 mg/m2 Intravenous